Free Trial

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from Brokerages

Phathom Pharmaceuticals logo with Medical background

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has earned an average recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.60.

A number of research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Monday, April 21st. HC Wainwright lowered their price target on Phathom Pharmaceuticals from $28.00 to $20.00 and set a "buy" rating for the company in a research report on Friday. Cantor Fitzgerald raised Phathom Pharmaceuticals to a "strong-buy" rating in a report on Tuesday, February 25th. Craig Hallum reaffirmed a "buy" rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Finally, The Goldman Sachs Group cut their price target on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday.

Check Out Our Latest Analysis on PHAT

Phathom Pharmaceuticals Price Performance

NASDAQ PHAT traded down $0.60 during trading on Tuesday, hitting $2.76. The company's stock had a trading volume of 4,676,435 shares, compared to its average volume of 1,066,073. Phathom Pharmaceuticals has a fifty-two week low of $2.71 and a fifty-two week high of $19.71. The company has a market cap of $192.23 million, a PE ratio of -0.49 and a beta of 0.15. The business's 50 day simple moving average is $4.96 and its 200-day simple moving average is $7.70.

Institutional Trading of Phathom Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company's stock worth $29,000 after acquiring an additional 4,050 shares in the last quarter. CWM LLC boosted its position in Phathom Pharmaceuticals by 20,997.1% during the first quarter. CWM LLC now owns 7,384 shares of the company's stock worth $46,000 after purchasing an additional 7,349 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Phathom Pharmaceuticals in the fourth quarter valued at approximately $74,000. Teacher Retirement System of Texas purchased a new stake in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $90,000. Finally, Rafferty Asset Management LLC acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at $90,000. Institutional investors and hedge funds own 99.01% of the company's stock.

About Phathom Pharmaceuticals

(Get Free Report

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

See Also

Analyst Recommendations for Phathom Pharmaceuticals (NASDAQ:PHAT)

Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?

Before you consider Phathom Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.

While Phathom Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Hottest AI Stock You Haven’t Bought Yet
This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines